Reporting owner · Q3 2026 · CIK 1825376

RA Capital Nexus Fund II, L.P.: insider trades.

RA Capital Nexus Fund II, L.P. reported 11 non-derivative transactions on 3 SEC ownership filings in Q3 2026: 0 open-market purchases and 0 sales, across 2 companies.

Transactions
11
Purchases (P)
0
Sales (S)
0
Companies
2
Name as filed
RA Capital Nexus Fund II, L.P.

Companies

CompanyRelationshipTransactions
Freenome, Inc. (FRNM)Director, TenPercentOwner7
Climb Bio, Inc. (CLYM)Director, TenPercentOwner4

Transactions

11 non-derivative rows. Shares and prices as filed.
DateCompanyCodeSharesPriceOwned afterFiling
2026-09-28Climb Bio, Inc.M10,000$7.8930,000Form 4
2026-09-28Climb Bio, Inc.M40,000$1.2970,000Form 4
2026-09-28Climb Bio, Inc.M10,000$3.4610,000Form 4
2026-09-28Climb Bio, Inc.M10,000$320,000Form 4
2026-07-20Freenome, Inc.A6,561,711—7,311,711Form 4
2026-07-20Freenome, Inc.A970,950—970,950Form 4
2026-07-20Freenome, Inc.A553,703—553,703Form 4
2026-07-20Freenome, Inc.A908,103—908,103Form 4
2026-07-20Freenome, Inc.A367,427—367,427Form 4
2026-07-20Freenome, Inc.A4,918,411$1012,230,122Form 4
2026-07-20Freenome, Inc.A336,965$101,245,068Form 4

Questions

What stock did RA Capital Nexus Fund II, L.P. buy or sell?

RA Capital Nexus Fund II, L.P. reported 11 non-derivative transactions on 3 SEC ownership filings in Q3 2026: 0 open-market purchases and 0 sales, across 2 companies.

Is RA Capital Nexus Fund II, L.P. the same person as other filers with this name?

This page covers SEC CIK 1825376 only. The SEC assigns each reporting owner a CIK, and people with the same name have different CIKs.

Source: SEC Insider Transactions Data Sets, Q3 2026. Reported as filed; we do not assess intent, performance or compliance. All filings for this CIK on SEC.gov.

Plain-text version for agents and LLMs: /insiders/ra-capital-nexus-fund-ii-l-p-1825376.md

Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Securities and Exchange Commission. Data is reproduced from public SEC filings and datasets. Not investment advice.